Latest news
Stay in the know about our progress, and visit our Newsroom
A Galapagos company
Redefining the future of cancer treatment with a decentralized, innovative T-cell manufacturing platform
CellPoint was a biotechnology company founded in 2018 in the Netherlands. They developed a decentralized T-cell manufacturing platform. In 2022 CellPoint was acquired by Galapagos. Since then, they have been united around a single purpose: to transform patient outcomes through life-changing science and innovation for more years of life and quality of life. Thus, we will be sharing all company updates, news, and insights on Galapagos’ website.
If you are looking for the acquisition details, we invite you to have a look at our factsheet.
Galapagos’ decentralized, innovative T-cell manufacturing platform consists of an end-to-end xCellit® workflow management and monitoring software system, a decentralized, functionally closed, automated manufacturing platform for cell therapies (using Lonza’s Cocoon®) and a proprietary quality control (QC) testing and release strategy.
The combination of these three core components allows for the administration of a fresh product, a median vein-to-vein time of 7 days (i.e. the time between T-cell collection and CAR-T infusion), and greater physicians oversight throughout the process.
Discover Galapagos’ decentralized, innovative T-cell manufacturing platform. It consists of an end-to-end xCellit™ workflow management and monitoring software system, a decentralized, functionally closed, automated manufacturing platform for cell therapies (using Lonza’s Cocoon®) and a proprietary quality control (QC) testing and release strategy.
Stay in the know about our progress, and visit our Newsroom
Read more about how we are #LivingInnovation in our stories
Looking for information about our company, our stock and our financials?